News Snapshot:
DUBLIN--(BUSINESS WIRE)--Dec 20, 2021-- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been added to ResearchAndMarkets.com 's offering. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recently identified immune checkpoint inhibitor which is being evaluated as potential immunotherapeutic target. TIGIT is transmembrane glycoprotein receptor with Ig-like V-type domain and an ITIM in its cytoplasmic domain and is expressed on wide range of cells including memory T-cells, NK cells, and Tregs. Apart from this, studies have demonstrated high expression of TIGIT on wide range of solid tumors and hematological malignancies, thus...
